Jazz Pharmaceuticals（JAZZ）株式概要
ジャズ・ファーマシューティカルズ plcは、米国、欧州、および国際的に医薬品の特定、開発、商業化を行う。 詳細
JAZZ Community Fair Values
Create NarrativeSee what 50 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Jazz Pharmaceuticals plc 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$239.01 |
| 52週高値 | US$242.18 |
| 52週安値 | US$105.00 |
| ベータ | 0.27 |
| 1ヶ月の変化 | 17.99% |
| 3ヶ月変化 | 40.93% |
| 1年変化 | 120.75% |
| 3年間の変化 | 85.12% |
| 5年間の変化 | 34.00% |
| IPOからの変化 | 1,248.05% |
最新ニュース
分析記事 • May 13
We Think You Can Look Beyond Jazz Pharmaceuticals' (NASDAQ:JAZZ) Lackluster Earnings
The market was pleased with the recent earnings report from Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ), despite the...分析記事 • May 08
Jazz Pharmaceuticals plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) investors will be delighted, with the company turning in some strong numbers...
ナラティブの更新 • Apr 28
JAZZ: HER2 GEA Data Will Support Future Oncology Leadership Thesis
Analysts have nudged the price target on Jazz Pharmaceuticals higher to about $226, reflecting updated views on margins, central nervous system revenue durability, and upcoming oncology contributions following recent Q4 results and refreshed models. Analyst Commentary Recent Street research on Jazz Pharmaceuticals has centered on refreshed models following Q4 results, updated revenue guidance, and the expected contribution from oncology assets alongside the core central nervous system portfolio.Recent updates
分析記事 • May 13
We Think You Can Look Beyond Jazz Pharmaceuticals' (NASDAQ:JAZZ) Lackluster Earnings
The market was pleased with the recent earnings report from Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ), despite the...分析記事 • May 08
Jazz Pharmaceuticals plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) investors will be delighted, with the company turning in some strong numbers...ナラティブの更新 • Apr 28
JAZZ: HER2 GEA Data Will Support Future Oncology Leadership Thesis
Analysts have nudged the price target on Jazz Pharmaceuticals higher to about $226, reflecting updated views on margins, central nervous system revenue durability, and upcoming oncology contributions following recent Q4 results and refreshed models. Analyst Commentary Recent Street research on Jazz Pharmaceuticals has centered on refreshed models following Q4 results, updated revenue guidance, and the expected contribution from oncology assets alongside the core central nervous system portfolio.
ナラティブの更新 • Apr 13
JAZZ: CNS Cash Flows And Upcoming Oncology Launches Will Shape Execution Risks
Analysts have increased their average price target on Jazz Pharmaceuticals by $13 to $255, citing more supportive assumptions around revenue growth, profit margins and a slightly lower future P/E following the recent Q4 results and updated guidance. Analyst Commentary Recent research on Jazz Pharmaceuticals has largely centered on updated price targets and ratings following the company’s Q4 report and new guidance.ナラティブの更新 • Mar 30
JAZZ: CNS Cash Flows And HER2 Franchise Will Shape Oncology Execution Risks
Narrative Update on Jazz Pharmaceuticals Analysts have lifted price targets on Jazz Pharmaceuticals by roughly $10 to $45 into a $224 to $275 range, citing steady central nervous system demand, updated Ziihera and zanidatamab expectations following HERIZON-GEA data, and recent Q4 results that aligned with or modestly exceeded prior forecasts. Analyst Commentary Recent research on Jazz Pharmaceuticals has been broadly constructive, with several firms adjusting price targets higher after Q4 results and the HERIZON GEA data updates.ナラティブの更新 • Mar 16
JAZZ: HER2 Data And CNS Cash Flows Will Balance Oncology Execution Risks
The analyst price target for Jazz Pharmaceuticals has been adjusted slightly higher to reflect a $1 increase in fair value to $188, lower modeled revenue growth at 2.92%, a higher profit margin assumption at 21.90%, and a reduced future P/E of 13.95, as analysts point to a resilient central nervous system franchise, updated views on Ziihera and zanidatamab opportunities, and recent Q4 results and guidance. Analyst Commentary Recent research coverage points to generally constructive sentiment on Jazz Pharmaceuticals, with a cluster of higher price targets anchored to the company’s central nervous system portfolio and oncology pipeline, including Ziihera and zanidatamab.
ナラティブの更新 • Mar 02
JAZZ: Oncology Readouts And CNS Durability Will Drive Future Upside Potential
Our analyst fair value estimate for Jazz Pharmaceuticals has moved from $230.00 to about $263.59, as analysts factor in stronger margin expectations, a slightly higher discount rate, and ongoing Street enthusiasm around Ziihera and the broader oncology pipeline following recent Q4 updates and HERIZON-GEA data presentations. Analyst Commentary Recent Street research has leaned constructive on Jazz Pharmaceuticals, with multiple bullish analysts revisiting their models following Q4 results and the latest HERIZON-GEA data.Seeking Alpha • Feb 26
Jazz Pharmaceuticals: Relief Rally On 2026 Oxybate Franchise's Outlook
Summary Jazz Pharmaceuticals is positioned for long-term value creation, with a relief rally following Q4 2025 results and 2026 outlook for the oxybate business. Jazz expects Xywav revenues to be flat or up mid-single digits in 2026, despite generic Xyrem headwinds, with the oxybate franchise revenues projected at $1.8-1.9 billion. Strong Modeyso launch and robust Ziihera phase 3 data in first-line GEA set up new growth drivers, with Ziihera's U.S. launch anticipated in 2H 2026. Multiple expansion and valuation re-rating are possible as investors look past widespread availability of Xyrem generics, with Ziihera and other assets supporting (at least) mid-single-digit revenue growth. Read the full article on Seeking Alpha
新しいナラティブ • Feb 21
Beyond the Patent Cliff: Unlocking the Cash Machine
Jazz Pharmaceuticals (JAZZ), headquartered in Dublin, Ireland, enters 2026 as a highly efficient cash generator that the broader market seems to continually misunderstand. Following a massive 41% earnings beat late last year, the company is proving that it is successfully navigating the transition away from its legacy reliance on the sleep disorder drug Xyrem.ナラティブの更新 • Feb 16
JAZZ: HER2 Practice-Changing GEA Data Will Drive Future Oncology Leadership
Narrative Update Overview The analyst price target for Jazz Pharmaceuticals has moved higher, with our fair value estimate rising from $213 to $219.40 as analysts factor in stronger Ziihera and zanidatamab potential, supported by recent HERIZON-GEA data and updated Street research. Analyst Commentary Recent Street research on Jazz Pharmaceuticals has been largely constructive, with multiple firms updating their work after the detailed HERIZON-GEA-01 readout and related discussions around Ziihera and zanidatamab.ナラティブの更新 • Feb 02
JAZZ: Practice-Changing HER2 Data Will Drive Oncology Upside And Rebalance Legacy Risks
Analysts have raised their price targets on Jazz Pharmaceuticals by approximately $10 to $30 per share, citing what they describe as practice-changing HERIZON GEA data for Ziihera and a clearer oncology pipeline driver as key supports for the higher valuations. Analyst Commentary Across recent research notes, analysts have been revising their views on Jazz Pharmaceuticals primarily around the HERIZON GEA data for Ziihera and what it could mean for the oncology portfolio.ナラティブの更新 • Jan 19
JAZZ: Practice-Changing HER2 Data Will Rebalance Oncology Potential And Legacy Risks
Jazz Pharmaceuticals' updated analyst price target has edged down by US$1 to US$187 as analysts factor in slightly higher growth and margin assumptions, supported by recent HERIZON-GEA-01 data that they describe as practice changing for Ziihera and potentially supportive of new standard-of-care use across several HER2+ cancer settings. Analyst Commentary Across recent research, most firms are reacting to the HERIZON-GEA-01 data by lifting their Jazz Pharmaceuticals price targets and highlighting Ziihera and zanidatamab as key value drivers.ナラティブの更新 • Jan 05
JAZZ: Oncology Data Will Reshape Revenue Mix While Legacy Headwinds Persist
We are raising our Jazz Pharmaceuticals fair value estimate to $188 from $147 as analysts boost price targets following positive HERIZON-GEA-01 data for Ziihera, which they see as a potential new standard of care and a multibillion dollar revenue driver. Analyst Commentary Street research following the HERIZON-GEA-01 topline readout has turned broadly constructive on Jazz Pharmaceuticals, with multiple firms lifting price targets and reiterating positive ratings.ナラティブの更新 • Dec 18
JAZZ: HER2-Positive GEA Breakthrough Will Drive Future Oncology Leadership
Analysts have nudged their fair value estimate for Jazz Pharmaceuticals higher to $213.00 from $208.50, reflecting stronger long term revenue growth expectations and a richer future P/E multiple, supported by increasingly bullish views on Ziihera's potential to become a new standard of care in HER2 positive GEA and a key oncology growth driver. Analyst Commentary Bullish analysts are largely focused on the upside from Ziihera's HERIZON-GEA-01 data, with multiple research shops lifting price targets and embedding higher long term oncology growth into their models.ナラティブの更新 • Dec 04
JAZZ: HER2-Positive GEA Success Will Drive Future Oncology Leadership And Upside
Our fair value estimate for Jazz Pharmaceuticals has nudged higher to $208.50 from $206.38, reflecting analysts' upward revisions to price targets as they factor in expectations of stronger long term revenue growth and profitability. This is driven by Ziihera's potential as a new standard of care in HER2 positive GEA and broader oncology indications.ナラティブの更新 • Nov 20
JAZZ: Recent Positive Trial Data Will Drive Future Leadership In HER2-Positive Oncology
Analysts have increased their price target for Jazz Pharmaceuticals from approximately $186 to $206 per share. They cite improved revenue growth projections and recent strong clinical data supporting the potential of Ziihera as a standard-of-care therapy in HER2-positive cancers.分析記事 • Nov 18
Improved Revenues Required Before Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 25% Jump Looks Justified
Despite an already strong run, Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) shares have been powering on, with a gain of...ナラティブの更新 • Aug 30
Emerging Therapies And Portfolio Expansion Will Shape Future Markets
Analysts have modestly raised their price targets for Jazz Pharmaceuticals, driven by growing confidence in Modeyso's commercial prospects and expanded market potential, partially offset by persistent challenges in other segments, resulting in a new consensus target of $186.47. Analyst Commentary Bullish analysts are increasingly positive on the commercial potential of Modeyso following its recent approval, citing higher-than-expected pricing, a dedicated launch strategy, and strong patient/prescriber interest.分析記事 • Aug 09
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Last week, you might have seen that Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) released its second-quarter result to the...分析記事 • Jul 21
Lacklustre Performance Is Driving Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Low P/E
With a price-to-earnings (or "P/E") ratio of 14.2x Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) may be sending bullish...分析記事 • Jul 03
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Dec 23
Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
Summary Jazz Pharmaceuticals' stock moved nicely higher post-3Q24 report and FDA approval of zanidatamab, despite challenges in its narcolepsy franchise from Avadel's Lumryz. Jazz's neuroscience franchise faces declining Xyrem sales but sees growth in Xywav and Epidiolex. Oncology growth is driven by zanidatamab's approval and other key drugs like Rylaze and Zepzelca, crucial for achieving Vision 2025 sales goals. An updated analysis around Jazz Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Nov 18
Jazz Pharmaceuticals: High Uncertainty, Low Risk
Summary Jazz Pharmaceuticals is transitioning from Xyrem to Xywav, a low-sodium version with lower cardiac risks but faces competition with more convenient dosing. Strong management with CEO Bruce Cozadd owning $50M+ in shares and a solid balance sheet with Net Debt/EBITDA under 3x. The stock was purchased at under 50% of Base Case NPV, making the downside risk in a Worst Case scenario very modest. Despite some uncertainty, strong financial results and promising pipeline data make the stock deeply undervalued and a continued hold. Read the full article on Seeking Alpha株主還元
| JAZZ | US Pharmaceuticals | US 市場 | |
|---|---|---|---|
| 7D | 2.9% | -0.1% | -0.3% |
| 1Y | 120.8% | 38.7% | 26.7% |
業界別リターン: JAZZ過去 1 年間で38.7 % の収益を上げたUS Pharmaceuticals業界を上回りました。
リターン対市場: JAZZ過去 1 年間で26.7 % の収益を上げたUS市場を上回りました。
価格変動
| JAZZ volatility | |
|---|---|
| JAZZ Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: JAZZ 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: JAZZの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2003 | 2,890 | Renee Gala | www.jazzpharma.com |
ジャズ・ファーマシューティカルズ plcは、米国、欧州、および国際的に医薬品の特定、開発、商業化を行っている。ナルコレプシーや特発性過眠症（IH）を伴うカタプレキシーや過度の日中の眠気（EDS）を治療するXywav、レノックス・ガストー症候群（LGS）、Dravet症候群（DS）、結節性硬化症複合体（TSC）に伴う発作を治療するEpidiolex、急性リンパ芽球性白血病やリンパ芽球性リンパ腫を治療するRylazeを提供している；急性リンパ芽球性白血病およびリンパ芽球性リンパ腫の治療薬であるEnrylaze、プラチナ製剤ベースの化学療法中または化学療法後に病勢進行した転移性小細胞肺癌の治療薬であるZepzelca、HER2陽性の胆道癌の治療薬であるZiihera、H3 K27M変異を有するびまん性正中線神経膠腫の治療薬であるModeyso、重度の静脈閉塞性疾患の治療薬であるDefitelio。また、HER2陽性の胃食道腺がん（GEA）および胆道がん（BTC）の治療薬として第3相試験中のザニダタマブ、H3 K27M変異を有するびまん性神経膠腫の治療薬としてドルダビプロン、新たに治療関連と診断された急性骨髄性白血病の治療薬としてヴィクセオスを開発している。さらに、ネオアジュバントおよびアジュバント乳がん治療薬としてZanidatamab、高リスクMDS、新規診断の高リスクAML未治療患者、ゲノム解析により層別化されたDe novo中リスクまたは悪性リスクAML治療薬としてVyxeos、第2相臨床試験中の褐色細胞腫および傍神経節腫治療薬としてJZP3507を開発中である。さらに、RafおよびRas変異腫瘍を治療するJZP815、固形腫瘍のIFN INDUKIN分子を治療するJZP898、欠神てんかんを治療するJZP047を開発しており、これらは第1相臨床試験中である。同社はRedx Pharma plc、Autifony Therapeutics Limited、Zymeworks Inc.、住友製薬株式会社、Werewolf Therapeutics, Inc.とライセンス契約および提携契約を結んでいる。ジャズ・ファーマシューティカルズは2003年に設立され、アイルランドのダブリンに本社を置いている。
Jazz Pharmaceuticals plc 基礎のまとめ
| JAZZ 基礎統計学 | |
|---|---|
| 時価総額 | US$14.90b |
| 収益（TTM） | US$29.45m |
| 売上高(TTM) | US$4.44b |
509.2x
PER（株価収益率3.4x
P/SレシオJAZZ は割高か？
公正価値と評価分析を参照収益と収入
| JAZZ 損益計算書（TTM） | |
|---|---|
| 収益 | US$4.44b |
| 売上原価 | US$377.25m |
| 売上総利益 | US$4.06b |
| その他の費用 | US$4.03b |
| 収益 | US$29.45m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 0.47 |
| グロス・マージン | 91.50% |
| 純利益率 | 0.66% |
| 有利子負債／自己資本比率 | 118.1% |
JAZZ の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/20 04:59 |
| 終値 | 2026/05/20 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Jazz Pharmaceuticals plc 17 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。48
| アナリスト | 機関 |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| null null | Baird |